Latest News - Product Launches and Updates

Tuesday, November 07, 2017 | Epilepsy & Seizure Disorders, FDA Approval/Clearance, Phase 3/4 Trials, Product Launches and Updates

Oral Vimpat Approved for Use in Pediatric Patients with Partial-Onset Seizures

The FDA approved a label extension for Vimpat (lacosamide, UCB) CV as an oral option for the treatment of partial-onset seizures (POS) in pediatric patients four years and older. The expanded ind…

Read the full story

Thursday, October 19, 2017 | Product Launches and Updates, Research and Publications

Phenogenetic Database For Stem Cell Models of Neurological Diseases Launched

Based on the results of a novel meta-analysis of all induced pluripotent stem cells, researchers have created an atlas of how cell characteristic in neurological and neurodegenerative diseases are lin…

Read the full story

Monday, October 09, 2017 | Epilepsy & Seizure Disorders, FDA Approval/Clearance, Product Launches and Updates

Next-Generation VNS System and Implantable Device Approved

LivaNova has received FDA approval for its next-generation Vagus Nerve Stimulation (VNS) Therapy Programming System for drug-resistant epilepsy. The FDA has also approved the company's SenTiv…

Read the full story

Wednesday, October 04, 2017 | FDA Approval/Clearance, Multiple Sclerosis & Immune Disorders, Product Launches and Updates

FDA Greenlights Two Generic Glatiramer Acetate Formulations for Relapsing MS

The FDA approved Mylan’s generic versions of glatiramer acetate, including a three-times weekly 40mg/mL formulation of glatiramer acetate and a once-daily 20mg/mL formulation…

Read the full story

Wednesday, September 20, 2017 | FDA Approval/Clearance, Headache & Pain, Product Launches and Updates

FDA Approves Intellis Device for Intractable Pain

The FDA has approved the Intellis platform (Medtronic) for the management of certain types of chronic intractable pain. The Intellis platform was designed to overcome limitations with current spinal c…

Read the full story

Friday, September 15, 2017 | Epilepsy & Seizure Disorders, FDA Approval/Clearance, Product Launches and Updates

Briviact Approved as Monotherapy for Partial-Onset Seizures

The FDA has approved a supplemental new drug application for Briviact (brivaracetam, UCB) CV as monotherapy for partial-onset (focal) seizures (POS) in patients 16 years and older with epile…

Read the full story

Thursday, September 14, 2017 | Epilepsy & Seizure Disorders, FDA Approval/Clearance, Product Launches and Updates

Aptiom Approved for Partial-Onset Seizures in Patients Four Years of Age and Older

The FDA has approved the supplemental New Drug Application (sNDA) to expand the indication for Aptiom (eslicarbazepine acetate, Sunovion) to include treatment of partial-onset seizures in childre…

Read the full story

Wednesday, July 19, 2017 | Product Launches and Updates

CSL Behring: FDA Accepts sBLA for Hizentra® for Chronic Inflammatory Demyelinating Polyneuropathy

The FDA has accepted for review CSL Behring’s supplemental Biologics License Application (BLA) for Hizentra®([Immune globulin subcutaneous [Human] 20% liquid) for the treatment for…

Read the full story

Friday, June 30, 2017 | Epilepsy & Seizure Disorders, Product Launches and Updates

VNS Therapy Approved in Children Ages Four Years and Older with Partial Onset Refractory Seizures

The FDA has approved the VNS Therapy (LivaNova) in patients as young as four years of age with partial onset refractory seizures. Originally approved for patients ages 12 years and older, VNS The…

Read the full story

Tuesday, May 16, 2017 | Product Launches and Updates, Research and Publications, Stroke & Cerebrovascular

Endovascular Intervention Found Effective for "Late Window" Stroke Patients: DAWN Trial Analysis

The window for reducing disability and improving functional independence in stroke patients receiving endovascular therapy could extend as far as 24 hours, according to preliminary results from the DA…

Read the full story

Thursday, May 04, 2017 | Multiple Sclerosis & Immune Disorders, Product Launches and Updates, Research and Publications

MS Topography App Launches

A new app that offers a new, visual way of understanding multiple sclerosis (MS) was recently launched at the American Academy of Neurology Annual Meeting in Boston. The app is a disease simulation th…

Read the full story

Wednesday, May 03, 2017 | Epilepsy & Seizure Disorders, Phase 3/4 Trials, Product Launches and Updates, Research and Publications

New Data Highlight Efficacy and Safety of Brain Responsive Neuromodulation for Reduction of Seizures

Two new studies offer long-term perspective on the efficacy and safety of brain responsive neuromodulation for the reduction of seizures. One study evaluated the effects of NeuroPace’s RNS Syste…

Read the full story

Wednesday, April 12, 2017 | FDA Approval/Clearance, Movement Disorders, Product Launches and Updates

First Treatment for Tardive Dyskinesia Approved in US

The FDA approved the selective VMAT2 inhibitor Ingrezza (valbenazine, Neurocrine Biosciences), making it the first treatment approved in the US to treat adults with tardive dyskinesia. The efficacy of…

Read the full story

Wednesday, January 25, 2017 | Dementia & Cognitive Disorders, FDA Approval/Clearance, Product Launches and Updates

Memory Impairment Screening Tool Gains FDA Clearance

The FDA has granted 510(k) clearance to CANTAB Mobile (Cambridge Cognition), a sensitive screening tool for the detection clinically-relevant memory impairment in older adults at the point of care. CA…

Read the full story

Thursday, January 19, 2017 | Epilepsy & Seizure Disorders, Personnel/Company News, Product Launches and Updates

Takeda and Ovid Strike Partnership to Develop Investigational Agent for Rare Pediatric Epilepsy

Takeda and Ovid Therapeutics are teaming up for the clinical development and commercialization of Takeda’s investigational new drug TAK-935, a novel CH24H inhibitor, in rare pediatric epilepsies…

Read the full story
Load More